TapImmune Prevails in Legal Dispute with Michael Gardner

International Arbitration Tribunal Finds in Favor of TapImmune Inc., and Awards the Company $196,204 in Damages SEATTLE–(BUSINESS WIRE)– TapImmune Inc. (TPIV), announces successful outcome of proceedings against Michael Gardner after almost 2 years of litigation. The International Center for Dispute Resolution International Arbitration Tribunal has found that Mr. Gardner made numerous false representations, did not…

Details

TapImmune Appoints Leading Immunotherapy Researcher to Chair Scientific Advisory Board

SEATTLE–(BUSINESS WIRE)– TapImmune Inc. (TPIV) is pleased to announce that Dr. Keith Knutson, PhD (www.vgtifl.org/keith-knutson-phd) has been appointed to chair the company’s scientific advisory board. Dr. Knutson is Director of the Cancer Vaccines and Immune Therapies Program at the Vaccine & Gene Therapy Institute of Florida, a nonprofit biomedical research institute in Port St. Lucie,…

Details

TapImmune Inc. is Pleased to Announce the Filing of New Intellectual Property Surrounding its Novel and Proprietary Platform Expression System PolyStart™

New Technology Significantly Enhances the Presentation of Desired Peptides on the Surface of Cells for Targeting to the Immune System SEATTLE–(BUSINESS WIRE)– TapImmune Inc. (TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has filed a new patent application for a novel…

Details

TapImmune Inc. is Pleased to Announce the Signing of an Exclusive Option Agreement for a New Phase 1 Clinical Program in Breast and Ovarian Cancer

SEATTLE–(BUSINESS WIRE)– TapImmune Inc. (TPIVD), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has signed an exclusive option agreement for a set of unique peptide epitopes targeting Folate Receptor Alpha in both breast cancer and ovarian cancer. Folate receptor alpha is expressed…

Details

TapImmune Chairman and CEO, Glynn Wilson, Ph.D. Provides Corporate Update on Company Progress

SEATTLE–(BUSINESS WIRE)– TapImmune Inc. (TPIVD) Chairman and CEO, Glynn Wilson, Ph.D., has issued the following letter to the shareholders. Dear Shareholders, Over the past few years TapImmune has developed a strong scientific and clinical position in immunotherapy but has lacked the financial resources to fully leverage it. To address this, we now announce the completion…

Details

Tapimmune Announces Development Of Advanced Immunotherapeutic Vaccine Expression And Delivery System

TapImmune is pleased to announce development of a revolutionary cost effective immunotherapeutic vaccine expression and delivery system. The novel platform is termed TapImmune’s PolyStart™ technology and has been strategically designed to directly enhance the immune system’s ability to stimulate either or BOTH cytotoxic killer and helper T-cell reactive proprietary peptides, known and expected to be…

Details